Kallyope

We are pleased to announce?that under the terms of our research collaboration with Novo Nordisk?to discover novel peptide therapeutics, a ligand identified by Kallyope has been licensed by Novo Nordisk for further development, including as a potential new mechanism for the treatment of #obesity. This is a significant scientific milestone stemming from the target discovery collaboration between the two companies. ? As Jay Galeota, president and CEO, Kallyope, notes,?“Novo Nordisk is one of the leaders in the discovery and development of therapeutics for obesity and diabetes, and we are excited that our strategic early discovery collaboration resulted in the identification of a promising novel ligand. This advancement further validates the value of our unique Klarity? discovery platform and our strength in early-stage discovery collaborations.”?Read more?https://lnkd.in/edkjZ5st?#DrugDiscovery?#DrugDevelopment

A recent @MIT Sloan School of Management interview with Kallyope CEO @Jay Galeota offers valuable insights into the opportunities and challenges ahead for business school graduates who are considering careers in the life sciences. Jay notes that “these career experiences often come with the relatively rare opportunity to dream about the possible and innovate around it, driven by strong sense of purpose,” and he encourages the next generation of innovators to “be on the lookout for ways to stay close to emerging ideas and lean into new, ambiguous, and oftentimes unfamiliar scenarios." Read more:?https://lnkd.in/eDuE4Tmz?#HealthcareCareers #PharmaCareers #BiotechCareers

Pleased to share that Kallyope is covered in The Wall Street Journal article on growth in the obesity market and biotech’s up-and-coming players. Brian Gormley's thoughtful reporting on new oral therapeutics features Kallyope in the section “Alternatives emerge,” noting the advancement of our two oral drugs, K-757 and K-833, in Phase 2 clinical trials, which aim to stimulate the release of appetite-suppressing hormones. Kallyope Chief Medical Officer Brett Lauring, M.D., Ph.D. says, “As the obesity-medications market matures, novel treatments will be needed.” READ MORE?https://lnkd.in/gXcYQcS7?#type2diabetes #obesitytreatment #obesityprevention

Kallyope CEO Jay Galeota offers insight in Scrip Asks about therapeutic advances in 2024; on the subject of?new developments in the treatment of obesity and type 2 diabetes, he says:?“I look forward to seeing how therapies like nutrient receptor agonists are further advanced to meet patients’ needs more broadly in the coming year.” Read more:?https://lnkd.in/eNRMWRb8?#type2diabetes?#obesitytreatment?#obesityprevention

Very pleased that Kallyope is the focus of a feature article by Biocentury Director of Biopharma Intelligence Stephen Hansen, “Translating bariatric surgery weight loss into a pill,” highlighting how our oral approach to treating #obesity differs from GLP-1 agonists. The piece provides? insight into how we’ve developed the unique nutrient receptor agonists K-757 and K-833, currently in Phase 2 clinical trials, that aim to?prolong? plasma levels of GLP-1 and other gut hormones, with the potential effect of reducing appetite and improving glucose control. Read more: https://lnkd.in/gKCEhyUQ #type2diabetes #obesitytreatment #obesityprevention

We’re pleased to share Jay Galeota's piece?in BioSpace, “Addressing the Obesity Epidemic: The Need for New Oral Agents,” that outlines the urgency of developing new therapeutic classes to benefit the many underserved patients living with #obesity.?Of 100 million adults with obesity in the U.S., only a small percent are treated, and multiple approaches, including oral treatments, will be critical to address unmet patient need. Read more: https://lnkd.in/ekX8TDku?#obesitytreatment?#obesityprevention

The Kallyope team marked the completion of our second year collaborating with Columbia University students enrolled in the Columbia Business School Healthcare Management, Design, and Strategy course. This year’s fantastic group — students Christine H., Shailen Sampath, Alejandro Sousa, Phillip Chung, and Sujaan Sanghvi, together with Kallyope's Maury Spadoto and Robert Barretto — had the opportunity to navigate strategic decision-making challenges in the healthcare industry by providing a strategic analysis of raising capital in today's biotech market — and they crushed it! At Kallyope, we’re proud to be Made in New York and thrilled to partner with one of our city’s most prestigious universities to help inspire future healthcare leaders. #columbiabusinessschool #entrepreneurship

Congratulations to Nancy Thornberry, founding CEO, chair of R&D, and board member of Kallyope, on being named to the board of directors of Vertex Pharmaceuticals, the Boston-based global biotechnology company dedicated to creating transformative medicines for people with serious and life-threatening diseases. All of us at Kallyope have long been benefiting from Nancy’s pioneering spirit, scientific and corporate leadership, and commitment to collaboration, and we are excited for her opportunity to work with Vertex to improve the lives of patients everywhere. Read more: https://lnkd.in/gJzPacaS